2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AssigneesIdenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National De La Recherche Scientifique
InventorsJean-Pierre Sommadossi, Paolo LaColla, Gilles Gosselin
Life of this patent
Estimating the term…
Abstract
The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase.
Claims39
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- wherein R is mono, di or triphosphate;
- a stabilized phosphate prodrug;
- acyl;
- sulfonate ester;
- or benzyl, wherein the phenyl group is optionally substituted;
- an amino acid;
- a carbohydrate;
- or other pharmaceutical acceptable leaving group which when administered in vivo provides a compound wherein R is independently H or phosphate.
Dependencies are inferred from the claim text.